SOLV:NYE-Solventum Corp. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 69.95

Change

0.00 (0.00)%

Market Cap

USD 10.78B

Volume

1.67M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
DOCS Doximity Inc

N/A

USD 7.30B
WEAV Weave Communications Inc

N/A

USD 0.86B
MPLN MultiPlan Corporation

N/A

USD 0.17B
AMWL American Well Corp

N/A

USD 0.15B
OWLT Owlet Inc

N/A

USD 0.07B
VEEV Veeva Systems Inc Class A

N/A

N/A
PHR Phreesia Inc

N/A

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

N/A

N/A
TDOC Teladoc Inc

N/A

N/A

ETFs Containing SOLV

XHE SPDR® S&P Health Care Eq.. 2.23 % 0.35 %

N/A

USD 0.23B
RSPH Invesco S&P 500® Equal.. 1.75 % 0.00 %

N/A

USD 1.02B
ISPE:LSE iShares S&P 500 Equal Wei.. 0.24 % 0.00 %

N/A

USD 0.48B
CSD Invesco S&P Spin-Off ETF 0.00 % 1.16 %

N/A

N/A
CSD Invesco S&P Spin-Off ETF 0.00 % 0.61 %

N/A

N/A
EUSA iShares MSCI USA Equal We.. 0.00 % 0.15 %

N/A

USD 0.81B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 10.78B 100% F 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.